Hypercalcaemia induced by excessive parathyroid hormone secretion in a patient with a neuroendocrine tumour.
Explore the source record for details and available documents.
Biomarkers, Tumor↗
Biomedical subjects
Anne Denizot
Publications and source records attributed to Anne Denizot.
Evaluation of quantitative measurement of thyroglobulin mRNA in the follow-up of differentiated thyroid cancer.
Detection of thyroid cancer by thyroglobulin (Tg) assay in peripheral blood is useful in the absence of residual thyroid tissue, but it requires thyrotropin stimulation for maximal sensitivity and is affected by circulating antithyroglobulin antibodies. To avoid these drawbacks, thyroglobulin mRNA (Tg mRNA) assay in circulating blood has been proposed. Initial studies showed that Tg mRNA assay was more positive in patients with metastasis than in cured patients. Further studies showed controversial data. We measured Tg mRNA in 26 patients undergoing levothyroxine (LT(4)) suppressive therapy after total thyroidectomy for thyroid cancer and in 11 controls. The stage of the cancer was defined according to the findings of the latest whole-body (131)I scan and serum Tg performed under LT(4) withdrawal. Patients were classified as cured (negative scan, negative stimulated Tg, 8 patients), with metastasis (positive scan in extrathyroid bed regions, positive Tg, 7 patients), with thyroid remnants (positive scan in thyroid bed, positive Tg, 8 patients), and discordant cases (negative scan, positive Tg, 3 patients). RNA was extracted from blood and analyzed by quantitative reverse transcription-polymerase chain reaction (RT-PCR) using two sets of primers and internal probes specific for Tg mRNA. This method allowed the detection of Tg mRNA in thyroid biopsies. Tg mRNA was undetectable in all control subjects and in all patients with cured cancer, positive in 1 of 8 patients with thyroid remnants, and in only 1 of 7 patients with metastasis. In conclusion, our data do not support the usefulness of Tg mRNA measurements in blood for monitoring thyroid cancer.
Adenocarcinoma, Follicular↗
Screening for primary hyperparathyroidism before thyroid surgery: A prospective study.
BACKGROUND: Misdiagnosed primary hyperparathyroidism (PHPT) during thyroid surgery may lead to a difficult reoperation. Because PHPT is often asymptomatic, calcium measurements have been recommended before thyroid surgery, but no study has focused on the results of a prospective PHPT screening. METHODS: The prospective study of 748 patients consisted of 2-step screening of calcium measurement in all patients (normal range, 2.2 to 2.6 mmol/L, 8.8 to 10.4 mg/dL). If the calcium level was greater than 2.49 mmol/L (9.9 mg/dL), parathyroid hormone level (PTH; normal range, 11 to 65 pg/mL) and second calcium measurements were obtained. Positive screening was defined by 2 calcium levels greater than 2.49 mmol/L (9.9 mg/dL) and PTH level greater than 49 pg/mL. In patients with negative screening, we evaluated the number of parathyroid incidentalomas. In patients with positive screening, we rated parathyroid adenomas discovered as "easily accessible" or "requiring specific dissection." We assumed that the former could have been incidentally found by a surgeon unaware of calcium value. The cost estimation was based on French national health system databases. RESULTS: In the 9 patients with positive screening, 9 had parathyroid adenomas, 3 of them requiring specific dissection. In the 739 patients with negative screening, 12 had surgical incidentalomas and 2 had postoperative PHPT diagnosis. CONCLUSIONS: Our screening was not exhaustive, but it avoided a reoperation for missed PHPT in 3 patients. Population screening cost less than 3 reoperations. Other strategies, more exhaustive and/or cost-effective, should be investigated.
Adolescent↗